Griffith University: Equality of opportunity bursaries support Griffith students indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.
India News: BITS pharmaceutical and data scientists will be working with CSIRO researchers and the Monash Institute of Pharmaceutical Sciences (Australia) to crea
Date Time
Researchers develop magnetised nanobeads to detect early-stage cancer
PhD candidate Zennia Jean Gonzaga and Professor Bernd Rehm (Griffith Institute for Drug Discovery), next to the bio-reactor which grows cell factories to make functional polymer particles.
Griffith University researchers have developed a new way to detect cancer biomarkers which could help diagnose early-stage disease.
They bioengineered cell factories to assemble nanobeads with magnetic properties that bind to specific target antibodies. Then the magnetised nanobeads were added to ovarian cancer cells to capture methylated DNA and exosomes (cells) to detect cancer.
“As the nanomaterials can be engineered according to the need for detecting a certain disease type, they are highly flexible and can be tuned for almost any kind of biological molecules that are relevant to detect specific diseases,” Professor Shiddiky said.
Professor Ron Quinn AM, Principal Research Leader at the Griffith Institute for Drug Discovery.
A new method of identifying molecular targets to fight disease could help accelerate future drug development new Griffith University research published in Scientific Reports has found.
“Even in this molecular era of drug discovery, there remain new investigational drugs whose molecular targets are unclear, restricting their optimisation and broad use in disease,” Professor Quinn said.
Protein 4J57 – “Plasmodium falciparum thioredoxin reductase-thioredoxin complex”
“A key step in the discovery of new pharmaceutical drugs and developing them to useful treatments for patients is, therefore, the identification of the molecular target while, at the same time, ensuring the drug does not interact with other gene products that would cause side effects.”